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Objectives: Recent recommendations by the Infectious Diseases Society of America for the treatment of
Staphylococcus aureus suggest the use of alternative agents when vancomycin MIC values are ≥2 mg/L. This
study examines the outcome of patients treated with daptomycin for S. aureus infections with documented
vancomycin MICs.
Patients and methods: All patients with skin, bacteraemia and endocarditis infections due to S. aureus with
vancomycin MIC values in CORE 2005–08, a retrospective, multicentre, observational registry, were studied.
The outcome (cure, improved, failure or non-evaluable) was the investigator assessment at the end of dapto-
mycin therapy. Success was deﬁned as cure or improved.
Results: Five hundred and forty-seven clinically evaluable patients were identiﬁed with discrete vancomycin MIC
values [MIC ,2 mg/L: 451 (82%); MIC ≥2 mg/L: 96 (18%)]. The vancomycin MIC groups were well matched for
patient characteristics, types of infections, ﬁrst-line daptomycin use (19%) and prior vancomycin use (58%).
Clinical success was reported in 94% of patients. No differences were detected in the daptomycin success
rate by the vancomycin MIC group overall or by the infection type. A multivariate logistic regression also
failed to identify vancomycin MIC as a predictor of daptomycin failure. Adverse event (AE) rates were not differ-
ent when analysed by MIC group; both groups had  17% of patients with one AE.
Conclusions: In this diverse population, daptomycin was associated with similar outcomes for patients, regard-
less of whether the vancomycin MIC was categorized as ,2o r≥2 mg/L. Further studies are warranted.
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Introduction
Increasing data suggest that vancomycin is losing its clinical
and microbiological potency against Staphylococcus aureus.
Vancomycin efﬁcacy is complicated by several ﬁndings. Multiple
published reports have noted a shift to higher vancomycin MIC
values within the accepted susceptibility range for S. aureus and
intermethod variability has been noted.
1–3 The susceptibility
breakpoint for vancomycin is deﬁned as ≤2 mg/L by the CLSI
and the FDA. However, this still results in a nearly 100% suscep-
tibility rate and does not allow for the microbiological identiﬁ-
cation of patients at a greater risk of failure.
4 Additionally,
there have been a number of reports of vancomycin treatment
failures for methicillin-resistant S. aureus (MRSA) isolates
with vancomycin MIC values of ≥2 mg/L compared with
≤1 mg/L.
5–8
A common response to these ﬁndings has been to utilize
higher vancomycin doses and trough serum concentrations, to
increase the likelihood of achieving antibiotic exposures necess-
ary for treatment. However, there are limited data to support
the safety of sustained trough serum vancomycin concentrations
of 15–20 mg/L, and several additional studies have suggested
that outcomes observed in patients with higher vancomycin
trough levels were no better than those seen in patients with
lower trough values.
9–12 Vancomycin activity is best predicted
by the AUC/MIC ratio and pharmacodynamic modelling suggests
that microbiological success or clearance is optimized when the
vancomycin AUC/MIC ratio exceeds 400.
13–15 Despite
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1784vancomycin trough levels of 15–20 mg/L, the achievement of an
AUC/MIC ratio of .400 is unlikely for isolates with a vancomycin
MIC of ≥2 mg/L. Therefore, it has been recommended that
alternative therapies should be considered.
13
Daptomycin is a cyclic lipopeptide antimicrobial agent with
extensive Gram-positive activity, including activity against
many vancomycin-resistant organisms. It is indicated for compli-
cated skin and skin structure infections (cSSSIs), as well as bac-
teraemia and right-sided endocarditis caused by MRSA and
methicillin-susceptible S. aureus (MSSA). Data exist that higher
vancomycin MIC values may correlate with similar shifts in the
distribution of MIC values of daptomycin.
16–20 Although the
mechanism is unclear, vancomycin-intermediate S. aureus
(VISA) isolates have variable susceptibility to daptomycin, but
these isolates remain relatively uncommon.
4,21,22 Recent data
suggest that daptomycin maintains bactericidal activity against
S. aureus with reduced susceptibility to vancomycin, including
heterogeneous VISA (hVISA) strains.
23 The clinical relevance of
these alterations in susceptibility has yet to be investigated.
The purpose of this analysis is to examine the clinical out-
comes in daptomycin-treated patients with S. aureus skin, bac-
teraemia and endocarditis infections with vancomycin MIC
values of ,2 mg/L versus those with MIC values of ≥2 mg/L.
Patients and methods
CORE
w (Cubicin
w Outcomes Registry and Experience) is a multicentre, ret-
rospective, observational study that collects the post-marketing experi-
ence with daptomycin in the USA. Data collection began in November
2003 and is ongoing. This study collects patient information, including
demographics, infections, treatments and outcomes at the end of dapto-
mycin therapy. This study was conducted in compliance with Institutional
Review Board (IRB) requirements at each site. After IRB approval, clinical
information was collected from medical records by trained study investi-
gators, most commonly an infectious disease physician along with a
research nurse or clinical pharmacist. A standardized case report form
was used to collect patient information.
Each year, sites either randomly selected (CORE 2005–06) or reported
on sequentially treated (CORE 2007–08) patients receiving daptomycin
at any dose or duration from those treated at each study site. The
sites were monetarily compensated for participation. The type of infec-
tion was determined by the principal investigator according to clinical
signs and symptoms, and microbiology culture reports. Patients were
not excluded for any underlying disease, such as severe renal or
hepatic impairment, or immunosuppression. In the subset assessed in
the current analysis, we included patients with a positive culture from
any site for S. aureus with a reported vancomycin MIC value that could
be categorized as ,2o r≥2 mg/L. Additionally, the analysis was
restricted to those patients evaluable for efﬁcacy for skin, bacteraemia
or endocarditis, classiﬁed as cure, improved or failure over the time
frame from January 2005 to December 2008.
The CORE methods from the ﬁrst year of the study have previously
been published.
24 From 2005 to present, multiple changes have been
implemented, including the collection of more detailed patient and infec-
tion details, susceptibility data, and adverse events (AEs).
Data collection for the CORE database
Both clinical and microbiological data were collected. Demographic data
collected included: age ranges (e.g. 18–30 years etc.); gender; weight;
renal function [creatinine clearance (CLCR) range] at daptomycin initiation
and at the end therapy (e.g. ,30 or ≥30 mL/min); type of dialysis, if
applicable; underlying diseases; patient location 48 h prior to daptomycin
initiation; prior antibiotic therapy; infection details; outcomes; discharge
information; efﬁcacy; and safety assessments. Culture results from
before or shortly after initiation of daptomycin were reported. Suscepti-
bility data for multiple antibiotics, including vancomycin, were collected,
if available, based on each institution’s individual local methods. Isolates
were not tested in a central laboratory. Details of daptomycin and other
antibiotic therapy collected include: daptomycin initial and ﬁnal dose;
dosing interval; and length of therapy. Other antibiotic therapy details
included prior, concomitant and follow-up antibiotics, and discontinu-
ation reason. Time to clinical response (investigators documented the
number of days that passed before there was a clinical improvement
based on signs and symptoms), as well as safety and efﬁcacy assess-
ments were documented, as described below.
Efﬁcacy assessment
Treatment responses were assessed by the investigator at the completion
of daptomycin therapy. Patients were considered evaluable for efﬁcacy
analysis (clinically evaluable) if the clinical response to daptomycin was
classiﬁed as cured, improved or failed. The clinically evaluable population
excluded those classiﬁed as non-evaluable. Cured was deﬁned as ‘clinical
signs and symptoms are resolved and/or no additional antibiotic therapy
necessary or infection cleared with a negative culture result reported at
end of therapy’. The infection was classiﬁed as improved if there was
‘partial resolution of clinical signs and symptoms and/or additional anti-
biotic therapy necessary at end of therapy’. Failed was deﬁned as
‘inadequate response to therapy; resistant, worsening or new/recurrent
signs and symptoms; a need for a change in antibiotic therapy; or positive
culture result reported at the end of therapy’. The infection response was
classiﬁed as non-evaluable if the investigator was ‘unable to determine
response at end of therapy because record did not contain adequate
information’. Beginning in 2007, when CORE began collecting reasons
for non-evaluability, the most frequent reason for a non-evaluable deter-
mination was ‘lost to follow-up’ (transfer to another institution to com-
plete daptomycin therapy). Treatment success was deﬁned as the sum
of cured and improved outcomes.
Safety assessment
All patients who received daptomycin were eligible for the safety analysis.
Throughout the daptomycin treatment period and up to 30 days follow-
ing the last dose of daptomycin, changes in physical ﬁndings, clinical
signs and symptoms, and laboratory values consistent with serious and
non-serious AEs were to be documented. The AE was serious if it resulted
in any of the following: death; was life-threatening; disability/incapacity;
hospitalization; congenital anomaly/birth defect; or an important
medical event. The following additional information was collected for
all AEs: day of onset relative to daptomycin start; severity (mild, moder-
ate or severe); relationship to daptomycin (not related or possibly
related); action taken with daptomycin (none, stopped permanently,
dose reduced or stopped temporarily); other action taken (none, conco-
mitant medication, procedure performed or other); outcome (resolved,
resolved with residual effects, death, ongoing or unknown); and resol-
ution (day of resolution or day of last contact relative to daptomycin
start).
Statistical analysis
Clinical outcome as reported was the outcome of interest. Categorical
variables were compared with the x
2 or Fisher exact test, as appropriate.
The multivariate logistic model was conducted using the methodology
previously described.
25 In that analysis, all CORE patients from 2005 to
2007 with infections due to S. aureus were studied and four variables
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JACwere found to be associated with failure: endocarditis; bacteraemia;
initial CLCR ,30 mL/min; and diabetes. Therefore, these pre-determined
risk factors were used in the analysis performed in this study. Statistical
signiﬁcance was deﬁned as P,0.05. All statistics were performed using
JMP, version 7.0, or SAS v.9.1.3 (SAS Institute, Cary, NC, USA).
Results
Patient demographics and characteristics
Of 4554 patients inCORE2005–08, therewere1370 patients with
skin,bacteraemiaorendocarditis infectionsduetoS.aureus.Eight
hundred and ﬁfty-ﬁve patients had a vancomycin MIC reported;
688 patients could be categorized into vancomycin MIC groups
of ,2o r≥2 mg/L. Patients with a reported MIC of ≤2 mg/L
(n¼167) could not be placed into these two categories and
were excluded. Of the 688 patients with categorizable vancomy-
cin MICs, 547 (80%) patients were evaluable for clinical
outcome (cure, improved or failure) and serve as the population
for all analyses. The patients excluded for vancomycin MICs of
≤2 mg/L and those non-evaluable for outcome had higher rates
of bacteraemia and endocarditis, and factors associated with
these diagnoses, such as daptomycin dose ≥6 mg/kg, CLCR
,30 mL/min and receipt of daptomycin in an intensive care unit
(ICU). The distribution of reported MIC values is shown in
Table 1. There were 451 isolates (82%) with a vancomycin MIC
of ,2 mg/L, of which 72% were MRSA, and the vancomycin MIC
≥2 mg/L group consisted of 96 (18%) isolates, of which 78%
were MRSA. Daptomycin MIC values were rarely reported; 64
(12%) patients had a daptomycin S. aureus MIC (61 were suscep-
tible to daptomycin and 3 had daptomycin MICs .1 mg/L).
Baseline demographics and characteristics of patients who
received daptomycin are shown in Table 2. The characteristics
appeared similar between the vancomycin MIC groups. The
majority of patients were older than 50 years of age, 51%
were male, 17% had an initial CLCR of ,30 mL/min and
10% were on dialysis. The median duration of daptomycin
therapy was 13 days (minimum 1, maximum 243) overall;
14.5 days (minimum1,maximum83) forbacteraemiaorendocar-
ditis patients and 13 days (minimum 1, maximum 243) for skin
infection patients. The median daptomycin dose was 4 mg/kg for
cSSSIs and uncomplicated skin and skin structure infections
(uSSSIs), and 6 mg/kg for endocarditis and bacteraemia; no
difference in the mean, median or percentage of patients receiv-
ing ≥6 mg/kg was seen between the vancomycin MIC groups.
The infection types are summarized in Table 3. The predomi-
nant indication was cSSSIs, while bacteraemia and endocarditis
comprised 30% of the population.
A majority of patients (442/547, 81%) received antibiotics
prior to beginning daptomycin. Of those receiving prior anti-
biotics, the most common were: vancomycin (n¼255, 58%);
clindamycin (n¼43, 10%); piperacillin/tazobactam (n¼37, 8%);
trimethoprim/sulfamethoxazole (n¼36, 8%); linezolid (n¼35,
8%); and ceftriaxone (n¼32, 7%). The prior antibiotic therapy
was reported as clinically failing in 194/442 (44%) patients. Of
those patients receiving prior vancomycin, 86 of 255 patients
(34%) switched due to failure. Vancomycin dosing was not col-
lected; however, the use, types and response to prior antibiotics
were similar between the vancomycin MIC groups.
Forty-seven percent (n¼256) of patients received concomi-
tant antibiotics with daptomycin. The most common concomi-
tant antibiotic in both vancomycin MIC groups was rifampicin
(,2 mg/L: 50/215, 23%; and ≥2 mg/L: 12/41, 29%), followed
overall by cefepime (n¼38, 15%), vancomycin (n¼37, 14%)
and piperacillin/tazobactam (n¼30, 12%).
Of the 287 patients categorized as improved, 187 (65%)
received antibiotics after daptomycin that had presumed activity
against the strain of S. aureus cultured. In these patients, the
most common reasons for using a follow-up antibiotic were
switch to oral antibiotic (n¼112), switch to less expensive anti-
biotic (n¼23) and narrowed spectrum (n¼11).
Efﬁcacy
Clinical success was reported in 94% of patients (42% cured and
52% improved). No differences were detected in the daptomycin
success rate by the vancomycin MIC group overall or by the infec-
tion type (Figure 1). It is interesting to note that the proportion of
patients identiﬁed as cured was higher in the vancomycin
≥2 mg/L group compared with the ,2 mg/L group for bacterae-
mia, cSSSIs and uSSSIs. A lower percentage of endocarditis
patients in the ≥2 mg/L group were reported as cured;
however, this comparison is based on a small number of patients
in this vancomycin MIC group. Daptomycin outcomes for
S. aureus with vancomycin MICs .2 mg/L (n¼11) were:
.2 mg/L, cSSSIs cured (n¼2) and uSSSIs cured (n¼5); 3 mg/L,
bacteraemia improved; 4 mg/L, cSSSIs cured (n¼2); and
.256 mg/L, bacteraemia cured.
Daptomycin was used as ﬁrst-line therapy with a 96% success
rate overall (45% cured, 51% improved), and the efﬁcacy was
similar in the ,2 mg/L group (84/86, 98%) and ≥2 mg/L group
(15/17, 88%) (P¼0.13, Fisher’s exact test). The concomitant
use of rifampicin and gentamicin predominantly occurred in
patients with bacteraemia or endocarditis. Combination treat-
ment with rifampicin success rates were: (i) in bacteraemia,
Table 1. Distribution of MIC values
Vancomycin MIC group [n (%)]
,2 mg/L (n¼451) ≥2 mg/L (n¼96)
≤0.2 ≤0.5 ,0.5 ¼0.5 ¼0.75 ≤1 ,1 ¼1 ¼1.5 ,2 .1
a ¼2 ≥2 .2 ¼3 ¼4 .256
1( ,1) 64 (14) 41 (9) 1 (,1) 1 (,1) 208 (46) 32 (7) 24 (5) 3 (,1) 76 (17) 2 (2) 82 (85) 1 (1) 7 (7) 1 (1) 2 (2) 1 (1)
MICs are the test results as reported in the patient records.
aIncluded in the ≥2 mg/L group given that the next higher 2-fold dilution would be 2 mg/L.
Crompton et al.
178619/22 (86%) with rifampicin versus 104/113 (92%) with no
rifampicin (P¼0.4); and (ii) in endocarditis, 8/11 (73%) with
rifampicin versus 11/14 (79%) with no rifampicin (P¼1.0).
Patients receiving rifampicin for bacteraemia or endocarditis
were older with greater renal dysfunction than those not receiv-
ing rifampicin. Gentamicin success rates in bacteraemia were 5/6
(83%) with gentamicin versus 118/129 (91%) with no gentami-
cin (P¼0.4) and in endocarditis were 5/8 (63%) with gentamicin
versus 14/17 (82%) with no gentamicin (P¼0.3). Gentamicin
patients were older and received daptomycin in an ICU more
often, but had a lower incidence of reduced initial renal function
than those not given gentamicin.
Both MIC groups received vancomycin prior to daptomycin
at similar rates and prior use of vancomycin did not have an
effect on the daptomycin success rates (238/255, 93%; 41%
cured and 52% improved) compared with those receiving a
Table 2. Demographics
Characteristic
Vancomycin MIC group
MIC ,2 mg/L (n¼451), n (%) MIC ≥2 mg/L (n¼96), n (%) all (n¼547), n (%)
Male 226 (50) 52 (54) 278 (51)
Age group (years)
≤50 193 (43) 41 (43) 234 (43)
51–65 147 (33) 27 (28) 174 (32)
≥66 111 (25) 28 (29) 139 (25)
Location 2 days before daptomycin administration
community 233 (52) 42 (44) 275 (50)
hospital 202 (45) 50 (52) 252 (46)
nursing home/extended care 14 (3) 4 (4) 18 (3)
unknown 2 (0.4) — 2 (0.4)
Daptomycin administration settings
a
inpatient 329 (73) 63 (66) 392 (72)
outpatient 241 (53) 59 (61) 300 (55)
Underlying diseases
b
hypertension 185 (41) 38 (40) 223 (41)
diabetes mellitus 142 (31) 31 (32) 173 (32)
other cardiovascular disease
c 103 (23) 19 (20) 122 (22)
cancer or transplant 51 (11) 14 (15) 65 (12)
chronic renal failure 47 (10) 10 (10) 57 (10)
peripheral vascular disease 33 (7) 10 (10) 43 (8)
anaemia/all haematological disease 33 (7) 8 (8) 41 (7)
chronic obstructive lung disease 33 (7) 8 (8) 41 (7)
ICU stay during daptomycin 52 (12) 10 (10) 62 (11)
CLCR ,30 mL/min at start of daptomycin 81 (18) 14 (15) 95 (17)
Dialysis at start of daptomycin 41 (9) 11 (11) 52 (10)
ICU, intensive care unit; CLCR, creatinine clearance.
aPatients may have both inpatient and outpatient daptomycin therapy.
bPatients may have more than one underlying disease; only underlying diseases ≥7% overall are shown.
cIncludes acute coronary syndromes, cardiac arrhythmias, valvular heart disease, congestive heart failure and unspeciﬁed cardiovascular disease.
Table 3. Infection types
Infection
Vancomycin MIC group
MIC ,2 mg/L (n¼451) MIC ≥2 mg/L (n¼96) all (n¼547)
cSSSIs 222 (49) 41 (43) 263 (48)
uSSSIs 103 (23) 21 (22) 124 (23)
Bacteraemia 107 (24) 28 (29) 135 (25)
Endocarditis 19 (4) 6 (6) 25 (5)
For patients with more than one reported infection type caused by
S. aureus, they were assigned to a single category by the following
hierarchy: endocarditis.bacteraemia.complicated skin and skin
structure infections (cSSSIs).uncomplicated skin and skin structure
infections (uSSSIs).
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53% improved) (P¼0.3, x
2 test). In addition, in patients receiving
prior vancomycin, clinical success rates were similar by MIC
group: ,2 mg/L, 198/211 (94%) and ≥2 mg/L, 40/44 (91%)
(P¼0.5, Fisher’s exact test). The percentage of patients failing
prior vancomycin therapy was similar in the two vancomycin
MIC groups. However, in the group of patients receiving prior van-
comycin, the daptomycin success rate was greater in patients
who had not failed vancomycin therapy [164/169 (97%) non-
failures versus 74/86 (86%) failures; P¼0.0009, x
2 test] and
was seen in both MIC groups. However, the vancomycin failure
group had higher incidences of several underlying diseases
(immunosuppression, acute renal failure and cardiac arrhyth-
mias) and a higher rate of initial CLCR ,30 mL/min (29% versus
15%; P¼0.01, Fisher’s exact test), which has been identiﬁed
as an independent predictor of failure in CORE patients with
S. aureus.
25
The crude analysis of failure for the vancomycin MIC group
≥2 mg/L compared with ,2 mg/L resulted in: odds ratio
(OR)¼1.86; 95% conﬁdence interval (CI), 0.8–4.3; P¼0.15. A
previous analysis identiﬁed four variables (endocarditis, bacter-
aemia, initial CLCR ,30 mL/min and diabetes) that were indepen-
dently associated with daptomycin failures.
25 After controlling
for these factors, the results for MIC group were essentially
unchanged: OR¼1.62; 95% CI, 0.6–4.2; P¼0.32. Only endo-
carditis (OR¼8.24; 95% CI, 2.4–27.8; P¼0.0007) and initial
CLCR ,30 mL/min (OR¼2.66; 95% CI, 1.1–6.4; P¼0.03)
remained predictive of daptomycin failure. The clinical outcomes
did not differ among the vancomycin MIC group of ≥2 mg/L
compared with the ,2 mg/L group.
Safety
Safety was assessed primarily as an indicator of the compar-
ability of the vancomycin MIC groups. AEs were reported in
80 (15%) patients overall. AE rates were not different when
analysed by MIC group: ,2 mg/L group (65/451, 14.4%) and
≥2 mg/L group (15/96, 15.6%) (P¼0.8, Fisher’s exact test).
Forty-two AEs were reported in 35 (6%) patients and were
classiﬁed by the sponsor as possibly related to daptomycin.
Two of these AEs (asthenia and rhabdomyolysis) in two
(0.4%) patients were assessed as meeting regulatory criteria
for seriousness; all resolved. There was no difference in mor-
tality by MIC group: ,2 mg/L group (10/451, 2.2%) and
≥2 mg/L group (2/96, 2.1%) (P¼1.0, Fisher’s exact test). The
mortality in the bacteraemia subgroup was 4.4%; ,2 mg/L
group (4/107, 3.7%) and ≥2 mg/L group (2/28, 7.1%). The
mortality in the endocarditis subgroup was 12%; ,2 mg/L
group (3/19, 15.8%) and ≥2 mg/L group (0/6).
Discussion
Vancomycin has been the mainstay in Gram-positive drug
therapy for over two decades. More recently, questions have
arisen about its limitations and effectiveness. In 2008, the FDA
lowered their recommended vancomycin susceptibility break-
point to match that of the CLSI, based on evidence of limited
success in infections due to S. aureus isolates with MICs of
.2 mg/L. However, these changes did not address the growing
data questioning the adequacy of the drug in isolates within
the currently deﬁned susceptible category. Sakoulas et al.
7 pub-
lished data on signiﬁcantly decreased clinical success rates in
MRSA bacteraemia patients with vancomycin MIC values of 1–
2 mg/L compared with those with MIC values of ≤0.5 mg/L. In
that patient population, clinical success with vancomycin
therapy was achieved in 55.6% of patients with isolate MICs of
≤0.5 mg/L versus 9.5% of cases with MICs of 1–2 mg/L
(P¼0.01).
7 However, the study involved patients unresponsive
to conventional therapy, including vancomycin, and the
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Figure 1. Clinical outcomes with daptomycin. For patients with more than one reported infection type caused by S. aureus, they were assigned to
a single category by the following hierarchy: endocarditis (Endo).bacteraemia (Bac).complicated skin and skin structure infections
(cSSSIs).uncomplicated skin and skin structure infections (uSSSIs).
Crompton et al.
1788authors warned of inappropriately applying the results to predict
treatment failure. Despite the limitations of that study, others
have correlated vancomycin MICs in MRSA isolates to diminished
outcomes. Several publications have shown increased rates of
mortality with MICs of 1.5–2 mg/L when compared with infec-
tions caused by lower-MIC isolates.
5,7,8,10,11 Soriano et al.
8 con-
cluded that a vancomycin MIC value of 2 mg/L was a
signiﬁcant predictor of mortality. Hidayat et al.
10 also demon-
strated signiﬁcantly lower end-of-treatment response rates
among their high (1.5–2 mg/L) MIC group (62% versus 85% in
the low-MIC group, P¼0.02). These studies used several different
methods, including Etest, agar diffusion and automated
systems, to reach similar agreement on the limitations of vanco-
mycin in isolates with measured MICs of 1.5–2 mg/L.
Of greater concern is the potential for the decreasing vanco-
mycin susceptibility to have an impact on daptomycin suscepti-
bility and, ultimately, clinical outcomes. Several small studies
describing local trends have shown in vitro evidence of a shift
in vancomycin MIC values (MIC creep).
1,2 In 2006, Wang et al.
2
published the largest study to date, which evaluated .6000 iso-
lates collected over 5 years, describing a vancomycin MIC creep
from an average vancomycin MIC value of ≤0.5 mg/L to one of
1 mg/L. In a smaller study of 662 isolates, Steinkraus et al.
1 eval-
uated trends in vancomycin MIC values over a 5 year period. All
isolates were susceptible to the tested antibiotics; however, sig-
niﬁcant increases in the geometric mean MIC values for vanco-
mycin were observed.
1 Data derived in these studies could,
however, be biased by the antimicrobial testing method used,
since it has been described that there is a lack of correlation
between antimicrobial testing methods for vancomycin (i.e.
broth microdilution, Etest, MicroScan and Vitek).
26,27 Daptomycin
has demonstrated almost complete activity against isolates with
various vancomycin MIC values, including MICs of 2 mg/L, hVISA
and vancomycin-resistant S. aureus.
4 Although daptomycin pos-
sesses a different mechanism of action compared with vanco-
mycin, there is a relationship for diminished daptomycin
activity against the relatively uncommon VISA population. A
recent surveillance study showed that 87% (13/15) of VISA iso-
lates tested were susceptible to daptomycin.
28 Additionally,
reports of daptomycin susceptibility changing under vancomycin
exposure have been described.
16 However, clinical results are of
greatest value and these concerns demonstrate a need for
further clariﬁcation, which served as the impetus for this study.
In our analysis, the vancomycin MIC for S. aureus isolates was
not a predictor of daptomycin treatment failure. This ﬁnding was
consistent across different infection types and in a multivariate
model accounting for factors previously determined to be associ-
ated with daptomycin failure. Of note, no signiﬁcant difference
was detected in the mortality or response rates in patients
receiving daptomycin based on vancomycin MIC grouping. Mor-
tality due to S. aureus bacteraemia or endocarditis has been
reported to be in the range of 20%–30%.
29,30 The relatively
low mortality rate in bacteraemia (4%) and endocarditis (12%)
patients may have been impacted by the retrospective data col-
lection, as patients or family were not contacted after discharge
to document outcomes. Additionally, the lack of efﬁcacy for dap-
tomycin in patients with pulmonary infections probably resulted
in an underrepresentation of patients with this signiﬁcant predic-
tor of death.
30 Lower success rates were seen for endocarditis
patients, underscoring the difﬁculty in treating this population
where appropriate adjunctive surgical therapy for source
control is important.
31
Additionally, prior exposure to vancomycin was not associ-
ated with diminished daptomycin outcomes. Moise et al.
17
demonstrated that there was an increase in the daptomycin
MIC values of MRSA isolated from patients on vancomycin
therapy and there have been limited published clinical data on
the effect of initial vancomycin treatment on daptomycin efﬁ-
cacy. Fowler et al.
31 showed that daptomycin was non-inferior
to the standard of care in the treatment of S. aureus bacteraemia
and right-sided endocarditis. In a subanalysis of all patients with
MRSA infections, Rehm et al.
32 demonstrated that previous van-
comycin treatment did not impact daptomycin success rates. Of
the patients randomized to daptomycin, 80% had previous treat-
ment with vancomycin and success rates for daptomycin were
comparable for patients with prior vancomycin treatment to
those who did not have prior vancomycin.
Although patients that failed prior vancomycin therapy
showed signiﬁcantly lower success rates with daptomycin treat-
ment, this occurred regardless of the MIC group, and was prob-
ably inﬂuenced by the greater severity of illness and potentially
higher bacterial load in this subset. Despite this statistical signiﬁ-
cance, success rates were still .85% for the group failing prior
vancomycin therapy and the overall success rate for all patients
was in the 90th percentile.
Limitations of our study include its retrospective design and
the potential for patient selection bias. Despite positive out-
comes with daptomycin, patient outcome was limited to an
assessment at the end of daptomycin therapy and the occur-
rence of relapsing infection should not be discounted. The
majority (71%) of patients in this study had skin and skin struc-
ture infections, and recurrence rates may be lower than with sys-
temic infections. However, the remaining patients had either
bacteraemia or endocarditis and in a prospective evaluation of
S. aureus bacteraemia, Fowler and colleagues found recurrent
S. aureus infection in 70 of 724 patients (9.6%) within
3 months of initial positive blood cultures.
33 This is comparable
to data from Chang et al.
34 that demonstrated a 9.4% recur-
rence rate within 6 months of initial positive blood cultures in a
prospective study of patients with S. aureus bacteraemia. The
possibility of recurrence must be considered in the evaluation
of the success rates in this study. Clinical isolates were not avail-
able for follow-up microbiological and molecular analysis. Testing
methodologies for MIC values were uncontrolled and based on
local practice. However, as previously noted, multiple studies
using varied testing methodologies have identiﬁed a vancomycin
MIC value of 1.5–2 mg/L as a risk factor for vancomycin failure.
Conﬁrmatory, standardized MIC values for both daptomycin
and vancomycin would provide additional information;
however, the shipping, freeze–thaw and passaging of isolates
often alters the vancomycin MIC values. Additionally, if the iso-
lates were available for testing, the underlying genotypic and
phenotypic determinants could have been determined, which
would be beneﬁcial for epidemiological purposes; though these
data are not available to physicians when making clinical
decisions. Further data on daptomycin MICs would have been
valuable in assessing the relationship with vancomycin MICs.
Daptomycin MICs were only documented in 12% of patients;
this low rate of reporting may be due to the retrospective
nature of collecting data and the selective reporting of
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some institutions do not conduct comprehensive daptomycin
MIC testing, since resistance to daptomycin in wild-type strains
is rare. This patient population represents contemporary dapto-
mycin use with its inherent prescribing variability and for
patient types often excluded from prospective study designs.
The proportion of vancomycin MIC values ≥2 mg/L reported in
this study was 17.6% (96/547), which is higher than what has
been reported in other studies.
35 This could be an advantage
of this retrospective study, where a selection bias for daptomycin
therapy resulted in a higher proportion of isolates with vancomy-
cin MIC values of ≥2 mg/L. It provides valuable data on these
S. aureus isolates with higher vancomycin MICs and provides a
signiﬁcant insight into a potential alternative therapy.
Despite the aforementioned limitations, this study summar-
izes the largest dataset to date on daptomycin use in patients
with a broad range of vancomycin MIC measurements for
S. aureus. These data suggest that daptomycin is an effective
and well-tolerated alternative to current treatment options,
including vancomycin, in patients with bacteraemia, endocarditis
or skin infections for isolates with vancomycin MIC values of
≥2 mg/L.
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